<![CDATA[FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma]]>
RegulatoryapprovedRP1NivolumabPositive
AI Analysis
Summary
The FDA has approved RP1 in combination with nivolumab for adults with advanced melanoma who have progressed on anti-PD-1 therapy. This represents a regulatory milestone for the combination treatment in a difficult-to-treat patient population.
Outcome Details
FDA approved RP1 plus nivolumab for adults with advanced melanoma who progressed on anti-PD-1 therapy
Importance:9/10
Sentiment:
0.95
FDA ApprovalOncologyMelanomaImmunotherapyCombination Therapy
Related Companies
Read the original article
Published by Cancer Network on August 6, 2026 8:06 PM